Drug Profile
CP 778875
Alternative Names: CP-778,875Latest Information Update: 13 Aug 2007
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperlipidaemics; Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Hyperlipidaemia
Most Recent Events
- 20 Dec 2006 Phase-II clinical trials in Atherosclerosis in USA (unspecified route)
- 20 Dec 2006 Phase-II clinical trials in Hyperlipidaemia in USA (unspecified route)